Filtered By:
Specialty: Endocrinology
Condition: Diabetes Type 2
This page shows you your search results in order of date.
Order by Relevance | Date
Total 651 results found since Jan 2013.
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Diabetes Metab. 2023 Sep 5:101474. doi: 10.1016/j.diabet.2023.101474. Online ahead of print.ABSTRACTStroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, this conclusion was derived from indirect comparisons in absence of any head-to-head randomised controlled trial (RCT). The present...
Source: Diabetes and Metabolism - September 7, 2023 Category: Endocrinology Authors: Andr é J Scheen Source Type: research
To support the use of NT-proBNP to better detect heart failure in patients with type 2 diabetes
ConclusionThese determinants might contribute to investigate the NT-proBNP in T2DM sufferers. A decision support system to appropriately ease the prescription of NT-proBNP might be therefore implemented in primary care settings.
Source: Endocrine - August 29, 2023 Category: Endocrinology Source Type: research
Investigation of Pancreatic-beta cells Role in the Biological Process of Ageing
CONCLUSION: Aging accelerates beta cell senescence by generating premature cell senescence, which is mostly mediated by high glucose levels. Despite higher plasma glucose levels, hepatic gluconeogenesis accelerates and adipose tissue lipolysis rises, resulting in an increase in free fatty acid levels in the blood and worsening insulin resistance throughout the body.PMID:37608675 | DOI:10.2174/1871530323666230822095932
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - August 23, 2023 Category: Endocrinology Authors: Rishabh Chaudhary Janvi Khanna Manni Rohilla Sumeet Gupta Seema Bansal Source Type: research
Role of GLP-1 receptor agonist in diabetic cardio-renal disorder: Recent updates of clinical and pre-clinical evidence
Curr Diabetes Rev. 2023 Aug 9. doi: 10.2174/1573399820666230809152148. Online ahead of print.ABSTRACTCardiovascular complications and renal disease is the growing cause of mortality in patients with diabetes. The subversive complications of diabetes such as hyperglycemia, hyperlipidemia and insulin resistance lead to an increase in the risk of myocardial infarction (MI), stroke, heart failure (HF) as well as chronic kidney disease (CKD). Among the commercially available anti-hyperglycemic agents, incretin-based medications appear to be safe and effective in the treatment of type 2 diabetes mellitus (T2DM) and associated ca...
Source: Current Diabetes Reviews - August 10, 2023 Category: Endocrinology Authors: Sanket Seksaria Bhaskar Jyoti Dutta Mandeep Kaur Ghanshyam Das Gupta Surendra H Bodakhe Amrita Singh Source Type: research
Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis
ConclusionIn patients with type 2 diabetes, the hypotensive effects of SGLT2i and GLP-1 RAs were significantly associated with a reduction in mortality and cardiorenal events. These findings suggest that the lowering BP effect could be seen as an additive indicator of cardiovascular protection by SGLT2i and GLP-1 RAs drugs.
Source: Acta Diabetologica - July 13, 2023 Category: Endocrinology Source Type: research
Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria - a prospective population-based cohort study
CONCLUSIONS: PCOS should be considered a significant risk factor for CVD. Future follow-up will show how the risk of CVD events develops after menopausal age.PMID:37436934 | DOI:10.1093/ejendo/lvad077
Source: European Journal of Endocrinology - July 12, 2023 Category: Endocrinology Authors: M M Ollila R K Arffman E Korhonen L Morin-Papunen S Franks J Junttila T T Piltonen Source Type: research
Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure
J Clin Endocrinol Metab. 2023 Jul 6:dgad398. doi: 10.1210/clinem/dgad398. Online ahead of print.ABSTRACTGlucagon-like peptide-1 receptor agonists (GLP-1 RA) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RA may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across patient's risk with a particular focus in HF. After a careful review of the literature, we challenge the c...
Source: The Journal of Clinical Endocrinology and Metabolism - July 6, 2023 Category: Endocrinology Authors: Jo ão Pedro Ferreira Abhinav Sharma Javed Butler Milton Packer Faiez Zannad Francisco Vasques-N óvoa Adelino Leite-Moreira Jo ão Sérgio Neves Source Type: research
Cardio-cerebrovascular Outcomes in MODY, Type 1 Diabetes, and Type 2 Diabetes: A Prospective Cohort Study
CONCLUSIONS: MODY diagnosed by genetic analysis represents higher prevalence than the clinical diagnosis in UK Biobank. The risk of incident cardio-cerebrovascular events in MODY ranks between type 1 diabetes and type 2 diabetes.PMID:37093977 | DOI:10.1210/clinem/dgad233
Source: The Journal of Clinical Endocrinology and Metabolism - April 24, 2023 Category: Endocrinology Authors: Hui-Xuan Wu Tian-Yao Chu Junaid Iqbal Hong-Li Jiang Long Li Yan-Xuan Wu Hou-De Zhou Source Type: research
High absolute neutrophil count with type 2 diabetes is associated with adverse outcome in patients with coronary artery disease: A large-scale cohort study
ConclusionThis study suggests that stratification of patients with elevated ANC and T2D could provide prognostic information for CAD patients undergoing PCI.
Source: Frontiers in Endocrinology - April 11, 2023 Category: Endocrinology Source Type: research
Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
CONCLUSIONSOur findings contribute to the understanding that second-line SU for glucose lowering are unlikely to increase CV risk or all-cause mortality. Given their potent efficacy, microvascular benefits, cost effectiveness, and widespread use, this study supports that SU should remain a part of the global diabetes treatment portfolio.
Source: Diabetes Care - March 21, 2023 Category: Endocrinology Source Type: research
